Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

capecitabine

capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.

OTHER

Best supportive care (BSC)

Best supportive care and following-up every 6-8 weeks

Trial Locations (1)

510060

SunYat-senU, Guangzhou

All Listed Sponsors
collaborator

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER

collaborator

Affiliated Cancer Hospital of Shantou University Medical College

OTHER

lead

Sun Yat-sen University

OTHER

NCT02460419 - Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter